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Abstract
Background: Analyses of utilization trends (cost drivers) allow us to understand changes in
colorectal cancer (CRC) costs over time, better predict future costs, identify changes in the use of
specific types of care (eg, hospice), and provide inputs for cost-effectiveness models. This
retrospective cohort study evaluated healthcare resource use among US Medicare beneficiaries
diagnosed with CRC between 1992 and 2002.
Methods: Cohorts included patients aged 66+ newly diagnosed with adenocarcinoma of the colon
(n = 52,371) or rectum (n = 18,619) between 1992 and 2002 and matched patients from the general
Medicare population, followed until death or December 31, 2005. Demographic and clinical
characteristics were evaluated by cancer subsite. Resource use, including the percentage that used
each type of resource, number of hospitalizations, and number of hospital and skilled nursing facility
days, was evaluated by stage and subsite. The number of office, outpatient, and inpatient visits per
person-year was calculated for each cohort, and was described by year of service, subsite, and
treatment phase. Hospice use rates in the last year of life were calculated by year of service, stage,
and subsite for CRC patients who died of CRC.
Results: CRC patients (mean age: 77.3 years; 44.9% male) used more resources than controls in
every category (P < .001), with the largest differences seen in hospital days and home health use.
Most resource use (except hospice) remained relatively steady over time. The initial phase was the
most resource intense in terms of office and outpatient visits. Hospice use among patients who died
of CRC increased from 20.0% in 1992 to 70.5% in 2004, and age-related differences appear to have
evened out in later years.
Conclusion: Use of hospice care among CRC decedents increased substantially over the study
period, while other resource use remained generally steady. Our findings may be useful for
understanding CRC cost drivers, tracking trends, and forecasting resource needs for CRC patients
in the future.
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Background
Colorectal cancer (CRC) is the third-most common cancer
type in the United States (not including basal and squa-
mous cell skin cancer), and the third-leading cause of can-
cer deaths among both men and women[1]. The total
annual cost of CRC care in the US population over age 65
has been estimated at $8 billion in 2002 dollars[2]. To our
knowledge, no previous studies have reported compre-
hensive data on temporal trends in healthcare utilization
for CRC patients, although studies have been published
on hospice use and end-of-life care among cancer patients
(including some CRC patients) [3-11].
In addition to aiding in the understanding of cost drivers,
the study of healthcare utilization patterns may lead to
cost-saving strategies in the care of CRC (eg, a shift from
more-expensive settings to less-expensive settings), and
may inform studies regarding the quality of care received
by CRC patients as indicated by quality markers including
hospice, skilled nursing, and home health care[10]. Inpa-
tient hospitalization is generally the largest cost driver for
any disease; therefore, it is vital to be aware of temporal
trends in hospitalization use in order to understand
changes in costs over time and to predict costs in the
future[12]. Finally, decisions on CRC screening can be
based on cost-effectiveness analyses and models that rely
on CRC cost and utilization studies, and such decisions
may depend on having accurate data inputs into these
models.
The goals of this study were to analyze the sociodemo-
graphic and clinical characteristics of a large cohort of
CRC patients, describe healthcare utilization associated
with CRC, and assess temporal trends in resource utiliza-
tion.
Methods
Data Source
The data source for this study was the linked Surveillance,
Epidemiology, and End Results (SEER)-Medicare data-
base, in which Medicare claims are linked to SEER registry
data as part of a collaborative project between the
National Cancer Institute and the Centers for Medicare
and Medicaid Services. Complete details of the linkage of
the SEER and Medicare data have been described else-
where[13,14]. The study's use of SEER-Medicare data was
approved by the National Cancer Institute, assuring
patient confidentiality. No other ethics board review was
required. In the SEER-Medicare database, patient demo-
graphic characteristics (such as age, sex, and race/ethnic-
ity), disease characteristics (such as stage), and resource
use details are obtained from hospitals, outpatient clinics,
laboratories, private practitioners, nursing homes, hos-
pices, death certificates, autopsy reports, and Medicare
claims data[15]. Part A of the Medicare program covers
inpatient hospitalizations, skilled nursing facility (SNF)
and home health care after a hospital stay, and hospice
care. Approximately 99% of Medicare beneficiaries are
enrolled in Part A. During this study's analysis period,
Medicare did not cover outpatient prescription drugs.
Medicare Part B covers physician services (except for rou-
tine visits), outpatient services, diagnostic tests, emer-
gency room visits, durable medical equipment (DME),
laboratory services, home health care that does not follow
a hospital stay, and other medical services and supplies.
Approximately 95% of Medicare beneficiaries are enrolled
in Part B[13].
Patient Selection and Follow-up
CRC Cohort
All patients aged 66 years and older with a new diagnosis
of malignant adenocarcinoma of the colon, rectum, or
anus (ie, presence of a SEER cancer site recode value
between 15 and 27 and one of the following ICD-O-3 his-
tology codes: 8140, 8210-11, 8220-21, 8260-63, 8470,
8480-81, or 8490) reported to a SEER registry between
January 1, 1992 and December 31, 2002 were identified
for possible inclusion in the CRC cohort. The index date
for each patient was defined as the date of his or her CRC
diagnosis.
We excluded patients who were enrolled in a health main-
tenance organization (HMO) at any point from 12
months pre-index through follow-up. Until recently,
HMOs were not required to submit claims for specific
services received by their enrollees, so including these
patients might have underestimated the total utilization
for the sample. We also excluded patients who were not
eligible for Part A and B Medicare benefits at any point
from 12 months pre-index through follow-up or who
were eligible for Medicare benefits based on end-stage
renal disease or disability. We excluded patients who had
any prior history of cancer, were initially diagnosed with
CRC at the time of death or autopsy, were not able to be
matched to an appropriate comparator (based on age, sex,
and geographic region), or were characterized as having
stage 0 or unknown stage disease.
Comparison Cohort
Patients in the comparison cohort were randomly selected
from a 5% sample of Medicare beneficiaries residing in
SEER areas who had not been reported to any of the SEER
registries as having CRC. As with CRC patients, compari-
son patients were excluded if they were enrolled in an
HMO or were not eligible for Medicare Part A and B ben-
efits at any point from 12 months before index through
follow-up. Comparison cohort patients were not required
to have used services in order to be selected for inclusion,
and they were allowed to develop cancers other than CRC
after their index date. One comparison patient of identicalBMC Health Services Research 2009, 9:227 http://www.biomedcentral.com/1472-6963/9/227
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age, sex, and geographic region was matched to each CRC
patient and assigned the same index date so that both
patients were followed over the same time period. When
more than one match was possible, comparators were
chosen at random.
Follow-up Period
Study patients were followed to evaluate outcomes from
their index date until death or the end of the Medicare
claims data (December 31, 2005), whichever came first.
When a person died before his or her matched compara-
tor, we continued to follow the comparator to record his
or her utilization until death or the end of the Medicare
claims data, whichever came first.
Study Measures
Medicare claims were scanned to identify resource utiliza-
tion, including physician office visits, outpatient hospital
or clinic use, inpatient hospitalization, SNF utilization,
and use of home health care and hospice. DME claims
were excluded because of incomplete diagnostic coding.
Data Analyses
The demographic and clinical characteristics of both
cohorts were described, including Deyo-Charlson comor-
bidity scores, which were calculated for the pre-index 12-
month period for each person and excluded cancer-
related comorbidities[16]. Healthcare utilization was ana-
lyzed by cancer subsite (colon or rectal), age at diagnosis,
stage at diagnosis, and year of service. The percentages of
patients receiving each type of care, number of visits, and
lengths of stay were evaluated over the entire follow-up
period. We calculated attributable use rates for each phase
by subtracting utilization among persons in the compari-
son cohorts from that among persons in the CRC cohorts
over the same time period. This resulted in estimates of
the excess numbers of visits per person-year, which were
reported by treatment phase for office, outpatient, and
inpatient utilization.
Resource use by phase was estimated as follows: 1) termi-
nal-phase resource use was assigned first, with the termi-
nal phase defined as the final year of life (all resource use
was considered terminal for patients surviving for less
than 13 months after diagnosis); 2) the initial phase was
the period, up to 12 months in duration, after diagnosis
and before the last year of life among those who lived at
least 13 months after diagnosis; and 3) the continuing
phase was the period between the first and last year of life
among patients with at least 36 months of survival.
Resource use by treatment phase was generated by year of
service from 1993-2002, the years during which it was
possible to fully evaluate each phase.
For our analysis of the use of hospice care, we selected
from our overall CRC cohort only those patients who died
of CRC during the study period. We then calculated the
percentage of patients who used hospice care in their last
year of life and reported these data by cancer subsite, year
of service, and age at death.
All statistical tests for differences between study and con-
trol cohorts were obtained using the Wilcoxon rank-sum
test using the Statistical Analysis Software (SAS) package
(Version 9.1, SAS Institute, Cary, NC).
Results
Patient Demographic and Clinical Characteristics
Selected demographic and clinical characteristics of the
CC, RC, combined CRC, and comparison cohorts are
shown in Table 1. In the combined CRC and comparison
cohorts, the average patient was approximately 77 years of
age, 45% were male, and 86% were white. The mean ± SD
Deyo-Charlson comorbidity score (excluding cancer) was
0.5 ± 1.0 for cancer patients and 0.4 ± 0.9 for controls;
scores were fairly consistent across all years (1992: 0.3 ±
0.8; 2002: 0.5 ± 1.0 in 2002 [data not shown]).
Across all years, CC was most commonly diagnosed at
stage II, whereas RC was most commonly diagnosed at
stage I. Interestingly, among both CC and RC patients, age
at diagnosis changed considerably over the period of anal-
ysis. In 1992, 43.7% of CC patients were aged 66-74 years,
40.2% were 75-84, and 16.1% were aged 85 years or
more. The corresponding distribution in 2002 was 45.9%,
35.5%, and 18.7%, indicating a trend toward older age at
diagnosis (data not shown). In 1992, the age distribution
was similar for RC patients: 45.4% were aged 66-74 years,
40.7% were 75-84, and 13.8% were 85 years or older. By
2002, there were more 75-84 year olds (44.3%) diagnosed
with RC than 66-74 year olds (40.5%), and the propor-
tion of those aged 85+ years had increased to 15.2% (data
not shown).
Healthcare Utilization
As would be expected, both CC and RC patients used sig-
nificantly more healthcare resources than matched com-
parison patients (Table 2). We did not detect a pattern of
differences in resource use in the comparison cohort when
examined by stage of their matched cancer patient, thus
the comparison cohort is shown as a whole. Compared to
non-CRC patients, CC and RC patients had an average of
about 2 years less follow-up time because of their higher
mortality rate. Despite the shorter follow-up, more CRC
patients were hospitalized and spent more days in the
hospital, more received home health care, and more spent
more time in a SNF (all P < .001).BMC Health Services Research 2009, 9:227 http://www.biomedcentral.com/1472-6963/9/227
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Resource utilization differed somewhat by cancer stage at
diagnosis, with stage II and III patients having the most
intense absolute service utilization rates by most measures
(Table 2). However, when calculated per survival month,
stage IV patients had higher utilization rates in all areas.
For example, stage IV patients spent more than 2 days per
month of follow-up in a hospital or SNF (approximately
1.5 days in a hospital and 0.5 days in a SNF per month),
compared to less than 1 day per month of follow-up
among patients diagnosed at stages I-III. Use of home
health care services ranged between approximately 50-
60% for all stages (vs. 35-36% among non-CRC patients),
with higher use rates among RC patients.
Figure 1 shows annualized trends in the excess number of
office (a) and outpatient clinic (b) visits and inpatient
stays (c) by cohort, treatment phase, and year of service
(ie, trends in resource use among CRC patients relative to
matched comparison patients). Trends in attributable use
rates reflect changes among both CRC patients and their
comparators. For example, between 1995-1996, office vis-
its decreased by 0.8 visits per person-year among RC
patients in the terminal phase and increased by 4.2 visits
among comparison patients in the terminal phase, lead-
ing to a relative decrease of 5 visits per person year in the
number of attributable office visits.
The initial phase of treatment was the most resource
intense among both CC and RC patients for all 3 types of
resource use, with RC patients having higher excess use
rates in most cases in the initial and terminal phases.
Among patients who died of CRC during the study period,
an overall proportion of 50.5% of CC and 53.0% of RC
patients used hospice services in the last year of life.
Among CC patients, the proportion of all decedents who
used hospice care in the last year of life increased from
21.6% in 1992 to 71.0% in 2002. Among RC patients, the
increase was from 16.1% in 1992 to 69.2% in 2002. In
earlier years, persons over age 85 were less likely to use
hospice services than younger patients, but this difference
Table 1: Demographic and clinical characteristics of patients with CRC and matched controls
Colon Cancer Cohort Rectal Cancer Cohort Overall CRC Cohort Comparison Cohort
N 52,371 18,619 70,990 70,990
Age (mean (± SD)* 77.5 (6.90) 76.5 (6.80) 77.3 (6.90) 77.3 (6.90)
Male* 42.8% 50.5% 44.9% 44.9%
Race/ethnicity
White, non-Hispanic 86.2% 86.9% 86.4% 86.8%
African American, non-Hispanic 7.8% 6.1% 7.3% 6.5%
Hispanic, any race 1.1% 1.2% 1.1% 1.9%
Other 5.0% 5.7% 5.2% 4.8%
Geographic region*
Northeast 19.3% 19.6% 19.4% 19.4%
Midwest 27.3% 27.6% 27.4% 27.4%
West 42.0% 42.4% 42.1% 42.1%
South 11.3% 10.4% 11.1% 11.1%
Charlson score (mean (± SD)1 0.5 (1.00) 0.4 (0.90) 0.5 (1.00) 0.4 (0.90)
Selected Charlson comorbidities
Chronic pulmonary/respiratory 
disease
8.9% 7.9% 8.6% 7.1%
Congestive heart failure 7.9% 6.0% 7.4% 5.9%
Diabetes without complications 10.1% 8.4% 9.6% 7.6%
Cerebrovascular disease 6.0% 4.8% 5.7% 5.7%
Myocardial infarction 3.2% 2.5% 3.0% 2.6%
Peptic ulcer 2.4% 1.5% 2.2% 1.2%
Other major conditions2 7.2% 7.2% 7.2% 7.3%
Stage at diagnosis (%)
Stage I 23.7% 32.4% 26.0% **
Stage II 34.6% 25.1% 32.1% **
Stage III 24.6% 22.2% 23.9% **
Stage IV 17.2% 20.2% 18.0% **
Source: Authors' calculations based on SEER-Medicare data, 1992-2005. 1Modified Charlson comorbidity index: excludes cancer-related 
comorbidities. 2Other major conditions include rheumatologic disease, mild liver disease, diabetes with complications, major liver disease, 
peripheral vascular disease, dementia, renal disease, hemiplegia or paraplegia, and AIDS.
*Variables used in matching cohorts
**Data not available/not applicableBMC Health Services Research 2009, 9:227 http://www.biomedcentral.com/1472-6963/9/227
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seemed to disappear starting around 2002 among both
CC and RC patients (Figure 2).
Discussion
Despite their shorter lifespans, about one-third more CC
and RC patients were hospitalized than were matched
controls, and CRC patients accrued about 10 more hospi-
tal days than did controls. CC patients were hospitalized
more often than were RC patients in both inpatient and
SNF settings, possibly because of the greater use of surgery
in CC patients. RC patients used more home health and
hospice services than did CC patients and, in the initial
and terminal phases, were more likely to use office, outpa-
tient, and inpatient services. Resource use was most
intense among stage IV patients when analyzed per
month of follow-up.
During our study period (1992-2005), we observed a
marked increase in the percentage of beneficiaries who
used hospice care. RC patients had slightly higher hospice
use rates than did CC patients, which is interesting in light
of the fact that RC patients have lower lifetime and per-
lifetime-year costs than do CC patients[17]. The observed
increase in hospice use is in line with national trends in
Table 2: Resource use among patients with CRC, by stage and overall, vs. matched controls
Variables CRC Patients Overall CRC 
Cohort
Comparison 
Cohort
Difference1
Stage
I
Stage
II
Stage
III
Stage
IV
Colon Cancer 
Cohort
N 12,431 18,095 12,859 8,986 52,371 52,371
Mean (± SD) 
months of follow-up
61.1 (39.8) 56.4 (40.9) 44.7 (38.1) 12.7 (19.3) 47.1 (40.7) 68.6 (39.8) -21.5
Inpatient use 94.4% 97.7% 97.5% 94.3% 96.3% 68.2% 28.1%
Mean (± SD) 
hospitalizations
3.6 (3.3) 3.6 (3.1) 3.5 (3.0) 2.3 (2.0) 3.4 (3.0) 2.4 (3.1) 1.0
Mean (± SD) 
hospital days
26.3 (31.8) 28.5 (30.3) 27.9 (26.8) 20.1 (18.9) 26.4 (28.4) 15.1 (25.7) 11.3
SNF use 35.8% 41.2% 38.6% 30.0% 37.4% 29.0% 8.4%
Mean (± SD) 
SNF days
13.3 (50.9) 15.1 (51.7) 12.5 (37.4) 6.6 (18.4) 12.5 (44.2) 9.7 (33.0) 2.9
Outpatient clinic 
use
94.5% 91.9% 92.0% 77.4% 90.1% 89.9% 0.1%
Office visit use 99.7% 99.7% 99.6% 98.8% 99.5% 96.2% 3.3%
Home health care 
use
48.4% 52.9% 53.5% 45.7% 50.7% 36.3% 14.4%
Rectal Cancer 
Cohort
N 6,041 4,681 4,134 3,763 18,619 18,619
Mean (± SD) 
months of follow-up
61.0 (39.9) 52.0 (40.0) 46.0 (37.1) 11.6 (17.3) 45.4 (40.1) 70.6 (40.2) -25.2
Inpatient use 92.8% 96.8% 98.0% 89.7% 94.3% 67.5% 26.9%
Mean (± SD) 
hospitalizations
3.6 (3.4) 3.7 (3.0) 3.8 (3.0) 2.0 (2.0) 3.3 (3.0) 2.4 (3.2) 1.0
Mean (± SD) 
hospital days
26.1 (30.4) 29.5 (28.1) 30.2 (28.0) 16.7 (16.6) 25.9 (27.4) 15.2 (26.0) 10.8
SNF use 35.4% 40.7% 37.3% 30.1% 36.1% 28.1% 8.0%
Mean (± SD) 
SNF days
13.0 (46.9) 14.2 (40.1) 11.8 (32.8) 6.9 (20.7) 11.8 (38.1) 9.6 (30.3) 2.2
Outpatient clinic 
use
95.5% 93.4% 95.1% 76.4% 91.1% 90.1% 1.0%
Office visit use 99.6% 99.6% 99.8% 98.8% 99.5% 96.3% 3.1%
Home health care 
use
54.5% 62.6% 63.9% 46.7% 57.0% 35.3% 21.8%
Source: Authors' calculations based on SEER-Medicare data, 1992-2005. Resource use calculated based on entire follow-up period, expressed on an 
annual basis.
1Difference between overall CRC cohort and comparison cohort. All P < .001.
SNF: Skilled nursing facilities
Note: Cohorts were matched on age, sex, and geographic regionBMC Health Services Research 2009, 9:227 http://www.biomedcentral.com/1472-6963/9/227
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Excess visits per person-year among patients with CRC, by treatment phase and year of service Figure 1
Excess visits per person-year among patients with CRC, by treatment phase and year of service.
	















         
 
!

"

#
$








"








%




%





!
&

'




()&	
(()&	
(*
+&	
((*
+&	
((!&&&,
(((!&&&,
	




%
&











         
 
!

"

#
$








"








%




%





!
&

'




()&	
(()&	
(*
+&	
((*
+&	
((!&&&,
(((!&&&,
	




)&%
&-'

.
.
.
.
.
.
.
.
.
.
         
 
!

"

#
$












'



%




%





!
&

'




()&	
(()&	
(*
+&	
((*
+&	
((!&&&,
(((!&&&,BMC Health Services Research 2009, 9:227 http://www.biomedcentral.com/1472-6963/9/227
Page 7 of 8
(page number not for citation purposes)
hospice use that may have been fueled, in part, by an
increase in the number of hospice providers[18]. Medi-
care spending on hospice services increased by 130%
from 2000 to 2004, and the percent of all Medicare bene-
ficiaries who use hospice care increased from 22% in 2000
to 31% in 2004[18]. Given the potential clinical[19] and
economic[20] benefits of hospice, it is noteworthy that
hospice use increased so dramatically in our sample.
Few previous studies of CRC have included utilization
data, and most have focused on hospice use. For example,
Lackan et al found an overall hospice use rate of 30.2%
among patients with breast, colorectal, lung, and prostate
cancer who died between 1991 and 1999[3]. A study by
Shugarman et al using 1993-1999 Medicare data to ana-
lyze age and gender differences in utilization rates for CRC
patients in their last year of life found an overall hospice
use rate of 48.0%, with younger patients more likely to
use hospice services[11]. As we have shown, it appears
that hospice use differences by age may have smoothed
somewhat in more recent years.
This study is subject to the limitations of the data source,
including potential coding errors, incomplete data, and
lack of generalizability to the non-Medicare population
[21-23]. While the elderly comprise the majority of
patients with CRC, this sample is not representative of all
US CRC patients. Despite these limitations, SEER-Medi-
care data have been used in numerous published studies
of CRC[24].
Conclusion
This retrospective database study of 13 years of data from
over 70,000 CRC patients found that Medicare beneficiar-
ies with CRC use significantly more resources than similar
individuals without CRC. The most intense outpatient,
inpatient, and office visit resource use was seen in the ini-
tial treatment phase. Over the study period, the use of hos-
pice among those who died of CRC increased
substantially, and age-related differences appear to have
moderated over time. Our findings may be useful for
understanding changes in costs and cost drivers over time,
Hospice use rates among CRC patients who died of CRC, by age at death, year, and subsite Figure 2
Hospice use rates among CRC patients who died of CRC, by age at death, year, and subsite.
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tracking trends, and forecasting resource needs for CRC
patients in the future.
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